Management of Neovascular AMD
暂无分享,去创建一个
[1] M. Cooper,et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[2] P. Beer,et al. VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS , 2006, Retina.
[3] David J. Wilson,et al. INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2007, Retina.
[4] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[6] Quan Dong Nguyen,et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. , 2009, Ophthalmology.
[7] Manju Patel,et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[8] A. Luff,et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases , 2007, British Journal of Ophthalmology.
[9] S. Michels,et al. Frühe Effekte nach systemischer und intravitrealer Bevacizumab (Avastin®)-Therapie bei neovaskulärer altersbedingter Makuladegeneration , 2006 .
[10] David T. Shima,et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.
[11] M. Larsen,et al. Treatment of choroidal neovascularization using intravitreal bevacizumab. , 2007, Acta ophthalmologica Scandinavica.
[12] N. Himes,et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. , 2004, The Journal of clinical investigation.
[13] N. Eter,et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. , 2008, American journal of ophthalmology.
[14] J. Stone,et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.
[15] D. Connolly,et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. , 1990, Cancer research.
[16] Peter K Kaiser,et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.
[17] Osamu Sawada,et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. , 2010, Investigative ophthalmology & visual science.
[18] P. D. de Jong,et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. , 2007, Ophthalmology.
[19] P. Rosenfeld,et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.
[20] D. Qian,et al. Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model , 2007, Clinical Cancer Research.
[21] K. Bartz-Schmidt,et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[22] U. Schmidt-Erfurth,et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study , 2008, British Journal of Ophthalmology.
[23] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[24] F. Tsai,et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. , 2008, American journal of ophthalmology.
[25] P. Rosenfeld,et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. , 2006, Ophthalmology.
[26] P. Mitchell,et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. , 2006, Archives of ophthalmology.
[27] Jennifer I. Lim,et al. Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes. , 2005, American journal of ophthalmology.
[28] S. Seregard,et al. A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age‐related macular degeneration of different durations , 2008, Acta ophthalmologica.
[29] E. Keshet,et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[30] Philip J Rosenfeld,et al. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[31] Mark Michels,et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.
[32] R. Harper,et al. Visual Acuity and Fixation Characteristics in Age-Related Macular Degeneration , 2007, Optometry and vision science : official publication of the American Academy of Optometry.
[33] R. Cuthbertson,et al. Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration , 1999, Toxicologic pathology.
[34] B. Zinman,et al. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. , 2003, Diabetes care.
[35] T. Wong,et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. , 2007, American journal of ophthalmology.
[36] Joan W. Miller,et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. , 1996, Investigative ophthalmology & visual science.
[37] M. Maia,et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[38] A. Nugent,et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. , 2009, Investigative ophthalmology & visual science.
[39] L. Damico,et al. DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[40] P T de Jong,et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration , 1995 .
[41] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[42] Arthur D. Fu,et al. INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION , 2007, Retina.
[43] D. Fong,et al. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. , 2010, Ophthalmology.
[44] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[45] S. Bakri,et al. Retinal pigment epithelial tear after intravitreal ranibizumab. , 2007, American journal of ophthalmology.
[46] Richard F Spaide,et al. INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[47] P. Kaiser,et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. , 2007, American journal of ophthalmology.
[48] N. Gabrić,et al. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. , 2007, Ophthalmology.
[49] P. Wiedemann,et al. Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. , 2001, Microvascular research.
[50] I. Scott,et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. , 2006, Investigative ophthalmology & visual science.
[51] Holger Gerhardt,et al. Neuropilin‐1 is required for endothelial tip cell guidance in the developing central nervous system , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.
[52] B. Liu,et al. The Pharmacology Study of a New Recombinant Human VEGF Receptor-Fc Fusion Protein on Experimental Choroidal Neovascularization , 2008, Pharmaceutical Research.
[53] H. Yamashita,et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[54] William J Feuer,et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[55] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[56] G. Palade,et al. Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.
[57] N. Gabrić,et al. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[58] A. Adamis,et al. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. , 2007, Developments in ophthalmology.
[59] P. Rosenfeld,et al. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide , 2006, British Journal of Ophthalmology.
[60] J. Gilbert,et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. , 2006, Investigative ophthalmology & visual science.
[61] P. D. de Jong,et al. Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.
[62] Dennis P. Han. Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis. , 2004, Transactions of the American Ophthalmological Society.
[63] R. Avery,et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[64] G. Garcı́a-Cardeña,et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.
[65] M. Farah,et al. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[66] S. Jayasena. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.
[67] P. Kaiser,et al. Neovascular Age-Related Macular Degeneration , 2012, Drugs.
[68] A Kijlstra,et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. , 1999, American Journal of Pathology.
[69] R. Azad,et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population , 2008, Japanese Journal of Ophthalmology.
[70] D. Connolly,et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.
[71] P. Campochiaro,et al. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. , 1999, Molecular vision.
[72] H. Tanihara,et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.
[73] J. Escardo,et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. , 2006, Human molecular genetics.
[74] J. Tiedeman,et al. Intravitreal Bevacizumab (Avastin®) in the Treatment of Retinal Angiomatous Proliferation , 2007 .
[75] E. Kohner,et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. , 1996, The British journal of ophthalmology.
[76] E. Ng,et al. Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases , 2006, Annals of the New York Academy of Sciences.
[77] F. Falcão-Reis,et al. INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY: One-Year Results , 2010, Retina.
[78] J. Rakic,et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[79] P. Rosenfeld,et al. COMPARISON OF 2.5 mg/kg AND 5 mg/kg SYSTEMIC BEVACIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Twenty-Four Week Results of an Uncontrolled, Prospective Cohort Study , 2008, Retina.
[80] S. Fekrat,et al. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. , 2008, American journal of ophthalmology.
[81] G. Yancopoulos,et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. , 2005, Cold Spring Harbor symposia on quantitative biology.
[82] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[83] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[84] H. Mizuno,et al. Crystal Structures of Novel Vascular Endothelial Growth Factors (VEGF) from Snake Venoms , 2005, Journal of Biological Chemistry.
[85] T. Yagi,et al. A requirement for neuropilin-1 in embryonic vessel formation. , 1999, Development.
[86] P. Campochiaro,et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. , 2009, Archives of ophthalmology.
[87] R. Acheson,et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results , 2008, Eye.
[88] N. Bressler. Antiangiogenic approaches to age-related macular degeneration today. , 2009, Ophthalmology.
[89] R. Spaide. Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.
[90] A. Schakal,et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. , 2008, American journal of ophthalmology.
[91] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[92] R K Jain,et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.
[93] C. Gonzales. ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM: An Exploratory Analysis , 2005, Retina.
[94] R. Folberg,et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. , 1998, Ophthalmology.
[95] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[96] A. Reiner,et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.
[97] Hung V. Nguyen,et al. The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*) , 1996, The Journal of Biological Chemistry.
[98] J. Jonas,et al. Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Exudative Age-Related Macular Degeneration and Diffuse Diabetic Macular Edema , 2007, Ophthalmic Research.
[99] Sander R. Dubovy,et al. SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[100] Ming-Chih Crouthamel,et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity , 2007, Molecular Cancer Therapeutics.
[101] A. Bazarbachi,et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. , 2006, American journal of ophthalmology.
[102] Neil M Bressler,et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. , 2007, Archives of ophthalmology.
[103] P. Mitchell,et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials , 2009, British Journal of Ophthalmology.
[104] R. Tibrewala,et al. VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[105] K. Yamashiro,et al. VEGF164 is proinflammatory in the diabetic retina. , 2003, Investigative ophthalmology & visual science.
[106] Joan W. Miller,et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.
[107] N. Eter,et al. Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Interim Results From the Sustain Trial , 2008 .
[108] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[109] K. Freund,et al. “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION , 2009, Retina.
[110] E S Gragoudas,et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.
[111] J. Slakter,et al. RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION , 2001, Retina.
[112] K. Alitalo,et al. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. , 1999, Current topics in microbiology and immunology.
[113] P. Campochiaro,et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. , 2000, The American journal of pathology.
[114] J. Wolfe,et al. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. , 2004, Experimental eye research.
[115] Joan W. Miller,et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.
[116] R. Bhisitkul,et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.
[117] I. Perlman,et al. ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) , 2006, Retina.
[118] Hong Li,et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys , 2008, Molecular vision.
[119] Sander R. Dubovy,et al. COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2009, Retina.
[120] L. Orci,et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. , 1991, Biochemical and biophysical research communications.
[121] P. Szurman,et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. , 2008, Ophthalmology.
[122] J. Jonas,et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. , 2007, Acta ophthalmologica Scandinavica.
[123] P. Abraham,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. , 2010, American journal of ophthalmology.
[124] R. Cuthbertson,et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.
[125] S. Seregard,et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.
[126] M. C. Donati,et al. Intravitreal Bevacizumab Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 6-Month Results of an Open-Label Uncontrolled Clinical Study , 2007, European journal of ophthalmology.
[127] M. Maia,et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. , 2008, Investigative ophthalmology & visual science.
[128] B. Keyt,et al. Solution structure of the heparin-binding domain of vascular endothelial growth factor. , 1998, Structure.
[129] S. Wolf,et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. , 2009, American journal of ophthalmology.
[130] A. Loewenstein,et al. VARIABILITY AMONG RETINA SPECIALISTS IN EVALUATING FLUORESCEIN ANGIOGRAMS OF PATIENTS WITH NEOVASCULAR AGERELATED MACULAR DEGENERATION , 2007, Retina.